Catalog No.S1390 Synonyms: GR 38032F
Molecular Weight(MW): 329.82
Ondansetron is a serotonin 5-HT3 receptor antagonist, used to prevent nausea and vomiting caused by cancer chemotherapy, and radiation therapy.
Purity & Quality Control
Choose Selective 5-HT Receptor Inhibitors
|Description||Ondansetron is a serotonin 5-HT3 receptor antagonist, used to prevent nausea and vomiting caused by cancer chemotherapy, and radiation therapy.|
|In vivo||Ondansetron decreases the intensity of withdrawal signs such as increased defecation, jumping and wet-dog shakes, elevated the nociceptive threshold values which are decreased by precipitated withdrawal, but produces no change in urination, rectal temperature or salivation.  Ondansetron and granisetron significantly enhances gastric emptying of glass beads and improves cisplatin-induced slowing of gastric emptying in rats.  Ondansetron exhibits a biphasic dose-response profile in mice, with antidepressant-like effects peaking at 0.1 mg/kg, in the forced swim and tail suspension tests. Ondansetron pretreatment augments the antidepressant effects of fluoxetine and venlafaxine but does not influence the effects of desipramine or 8-hydroxy-2-(di-n-propylamino) tetralin. Ondansetron (10 mg/kg) reverses hyperactivity in the open field, and decreases the percentage entry and time spent in open arms in the elevated plus maze.  Ondansetron, a selective and potent 5HT3 receptor antagonist, is shown to be effective at blocking the amphetamine-induced disruption of LI at a dose of 0.01 mg/kg, but not at 0.1 mg/kg. Ondansetron is able to attenuate increases in dopamine activity, produces pharmacologically with amphetamine without affecting baseline dopamine activity.  Ondansetron facilitates performance in young adult and aged animals, and inhibits an impairment in habituation induced by scopolamine, electrolesions or ibotenic acid lesions of the nucleus basalis magnocellularis. Ondansetron and arecoline antagonizes a scopolamine-induced impairment. |
-  Pinelli A, et al. Eur J Pharmacol,?997, 340(2-3), 111-119.
-  Miyata K, et al. Jpn J Pharmacol,?995, 69(3), 205-214.
-  Ramamoorthy R, et al. Behav Pharmacol,?008, 19(1), 29-40.
|In vitro||DMSO||66 mg/mL (200.1 mM)|
|Water||24 mg/mL (72.76 mM)|
|Ethanol||10 mg/mL (30.31 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03785691||Recruiting||Drug: Mirtazapine|Drug: Ondansetron|Drug: Placebo||Hyperemesis Gravidarum|Nausea Gravidarum|Vomiting of Pregnancy||Nordsjaellands Hospital|Bispebjerg Hospital|Aalborg University Hospital|Aarhus University Hospital|Herlev and Gentofte Hospital|Hvidovre University Hospital|Odense University Hospital|Rigshospitalet Denmark|Regionernes Medicinpulje||March 1 2019||Phase 2|
|NCT03642964||Active not recruiting||Drug: CTC-501||Major Depressive Disorder (MDD)||Chase Therapeutics Corporation||September 10 2018||Phase 2|
|NCT02991456||Recruiting||Drug: Rolapitant|Drug: Ondansetron||Chemo-radiation Induced Nausea and Vomiting||Duke University|TerSera Therapeutics||October 9 2017||Phase 2|
|NCT04030884||Completed||Dietary Supplement: Honey and water mixture||Postoperative Nausea and Vomiting||OYA GUMUSKAYA BRADLEY|Istanbul University-Cerrahpasa||May 3 2017||Not Applicable|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.